Renal cell carcinomas mass of <4 cm are not always indolent

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Renal cell carcinomas mass of <4 cm are not always indolent. / Azawi, Nessn H; Lund, Lars; Fode, Mikkel.

In: Urology Annals, Vol. 9, No. 3, 2017, p. 234-238.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Azawi, NH, Lund, L & Fode, M 2017, 'Renal cell carcinomas mass of <4 cm are not always indolent', Urology Annals, vol. 9, no. 3, pp. 234-238. https://doi.org/10.4103/UA.UA_18_17

APA

Azawi, N. H., Lund, L., & Fode, M. (2017). Renal cell carcinomas mass of <4 cm are not always indolent. Urology Annals, 9(3), 234-238. https://doi.org/10.4103/UA.UA_18_17

Vancouver

Azawi NH, Lund L, Fode M. Renal cell carcinomas mass of <4 cm are not always indolent. Urology Annals. 2017;9(3):234-238. https://doi.org/10.4103/UA.UA_18_17

Author

Azawi, Nessn H ; Lund, Lars ; Fode, Mikkel. / Renal cell carcinomas mass of <4 cm are not always indolent. In: Urology Annals. 2017 ; Vol. 9, No. 3. pp. 234-238.

Bibtex

@article{1f864e23cc854466a15d5ebba0b76748,
title = "Renal cell carcinomas mass of <4 cm are not always indolent",
abstract = "CONTEXT: The rate of progression to metastatic disease in patients undergoing active surveillance for small renal tumors varies in the literature between 1% and 8%.AIMS: This study aims to examine the incidence of metastasis in small renal tumors of <4 cm in a Danish cohort.SETTINGS AND DESIGN: Retrospective.MATERIALS AND METHODS: Data on 106 patients who were diagnosed with renal cancer (RCC) of <4 cm by CT scan from January 2005 to December 2013 were collected retrospectively in January 2016 from patient charts and analyzed.STATISTICAL ANALYSIS USED: The cancer-specific survival (CSS) and overall survival (OS) were estimated using Kaplan-Meier methods.RESULTS: The mean age was 62 years (range 40-84 years). Two patients (1.9%) had metastases at the time of diagnosis. Radical nephrectomy was performed in 74 patients (70%); of them, one patients (1.4%) experienced late metastasis (LM). Partial nephrectomy was performed in 30 patients (28%); of them, two patients (6.7%) experienced LM. The mean time to LM was 27 ± 12 months (95% confidence interval: 4-56). CSS rates were 98%, 97%, and 97% for 1, 3, and 5 years, respectively, while OS rates were 96%, 92%, and 86% for 1, 3, and 5 years, respectively. On multivariate analysis, tumor size (P = 0.04), pT3a (P = 0.0017), and patient's age (P = 0.02) at the time of diagnosis were significant predictors of LM.CONCLUSIONS: Even small renal carcinomas may be aggressive, and caution should be taken when offering active surveillance.",
author = "Azawi, {Nessn H} and Lars Lund and Mikkel Fode",
year = "2017",
doi = "10.4103/UA.UA_18_17",
language = "English",
volume = "9",
pages = "234--238",
journal = "Urology Annals",
issn = "0974-7796",
publisher = "Medknow Publications and Media Pvt. Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Renal cell carcinomas mass of <4 cm are not always indolent

AU - Azawi, Nessn H

AU - Lund, Lars

AU - Fode, Mikkel

PY - 2017

Y1 - 2017

N2 - CONTEXT: The rate of progression to metastatic disease in patients undergoing active surveillance for small renal tumors varies in the literature between 1% and 8%.AIMS: This study aims to examine the incidence of metastasis in small renal tumors of <4 cm in a Danish cohort.SETTINGS AND DESIGN: Retrospective.MATERIALS AND METHODS: Data on 106 patients who were diagnosed with renal cancer (RCC) of <4 cm by CT scan from January 2005 to December 2013 were collected retrospectively in January 2016 from patient charts and analyzed.STATISTICAL ANALYSIS USED: The cancer-specific survival (CSS) and overall survival (OS) were estimated using Kaplan-Meier methods.RESULTS: The mean age was 62 years (range 40-84 years). Two patients (1.9%) had metastases at the time of diagnosis. Radical nephrectomy was performed in 74 patients (70%); of them, one patients (1.4%) experienced late metastasis (LM). Partial nephrectomy was performed in 30 patients (28%); of them, two patients (6.7%) experienced LM. The mean time to LM was 27 ± 12 months (95% confidence interval: 4-56). CSS rates were 98%, 97%, and 97% for 1, 3, and 5 years, respectively, while OS rates were 96%, 92%, and 86% for 1, 3, and 5 years, respectively. On multivariate analysis, tumor size (P = 0.04), pT3a (P = 0.0017), and patient's age (P = 0.02) at the time of diagnosis were significant predictors of LM.CONCLUSIONS: Even small renal carcinomas may be aggressive, and caution should be taken when offering active surveillance.

AB - CONTEXT: The rate of progression to metastatic disease in patients undergoing active surveillance for small renal tumors varies in the literature between 1% and 8%.AIMS: This study aims to examine the incidence of metastasis in small renal tumors of <4 cm in a Danish cohort.SETTINGS AND DESIGN: Retrospective.MATERIALS AND METHODS: Data on 106 patients who were diagnosed with renal cancer (RCC) of <4 cm by CT scan from January 2005 to December 2013 were collected retrospectively in January 2016 from patient charts and analyzed.STATISTICAL ANALYSIS USED: The cancer-specific survival (CSS) and overall survival (OS) were estimated using Kaplan-Meier methods.RESULTS: The mean age was 62 years (range 40-84 years). Two patients (1.9%) had metastases at the time of diagnosis. Radical nephrectomy was performed in 74 patients (70%); of them, one patients (1.4%) experienced late metastasis (LM). Partial nephrectomy was performed in 30 patients (28%); of them, two patients (6.7%) experienced LM. The mean time to LM was 27 ± 12 months (95% confidence interval: 4-56). CSS rates were 98%, 97%, and 97% for 1, 3, and 5 years, respectively, while OS rates were 96%, 92%, and 86% for 1, 3, and 5 years, respectively. On multivariate analysis, tumor size (P = 0.04), pT3a (P = 0.0017), and patient's age (P = 0.02) at the time of diagnosis were significant predictors of LM.CONCLUSIONS: Even small renal carcinomas may be aggressive, and caution should be taken when offering active surveillance.

U2 - 10.4103/UA.UA_18_17

DO - 10.4103/UA.UA_18_17

M3 - Journal article

C2 - 28794588

VL - 9

SP - 234

EP - 238

JO - Urology Annals

JF - Urology Annals

SN - 0974-7796

IS - 3

ER -

ID: 195546476